Patents by Inventor Mark D. Crew

Mark D. Crew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040225112
    Abstract: Single chain polypeptide forms of HLA-E useful in manipulating and ascertaining natural killer (NK) cell function are disclosed. The single chain trimer (SCT) form of HLA-E is comprised of the signal peptide from human beta-2 microglobulin (&bgr;2m), a canonical HLA-E binding peptide, a fifteen amino acid linker, mature human &bgr;2m, a twenty amino acid linker, and mature HLA-E heavy chain. The single chain dimer (SCD) form of HLA-E is comprised of the signal peptide from human &bgr;2m, mature human &bgr;2m, a twenty amino acid linker, and mature HLA-E heavy chain. The disclosed polypeptides can be used to inhibit NK cell cytotoxicity and cytokine production, enumerate and/or purify NK cell subsets, and identify biologically relevant HLA-E ligands. The disclosed HLA-E SCT and SCD nucleic acid sequences can be used a platform for synthesis of additional biologically active major histocompatibility class I protein single chain trimers and dimers.
    Type: Application
    Filed: May 6, 2003
    Publication date: November 11, 2004
    Inventor: Mark D. Crew
  • Publication number: 20030118568
    Abstract: The invention comprises exploiting viral stealth mechanisms to eliminate pig MHC class I cell-surface expression. PK(15) (pig kidney) cells stably transfected with the Herpes Simplex Virus (HSV) ICP47 gene [PK(15)-ICP47 cells] exhibited a dramatic reduction of MHC class I cell-surface expression when compared to untransfected PK(15) cells. To test the effect of down-regulation of porcine MHC class I on human cellular immune responses, a human CD8+ enriched T cell line (anti-PK15 T cells) with reactivity towards PK(15) cells was derived by repeated stimulation of human T cells with PK(15) cells stably transfected with the co-stimulatory molecule B7.1 [PK(15)-B7.1 cells]. Anti-PK15 T cells efficiently lysed PK(15) cells but not PK(15)-ICP47 (class I negative) cells. Consistent with effector function, anti-PK15 T cells showed a robust proliferative response to PK(15)-B7.1 cells but did not proliferate at all to PK(15)-B7.1 cells which also expressed HSV ICP47.
    Type: Application
    Filed: November 19, 2002
    Publication date: June 26, 2003
    Applicant: Board of Trustees of the University of Arkansas
    Inventor: Mark D. Crew